Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)

Inclusion Criteria:

- Have histologically confirmed Diffuse Large B Cell Lymphoma that is either:

- Refractory to first or later treatment, or

- First or later relapse AND has received at least 2 prior therapies (one of which
can be frontline therapy) or

- Relapsed post-autologous HSCT

- Have measureable disease

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

- Life expectancy of ≥ 12 weeks in the opinion of the Investigator

- Subject must be able to provide an evaluable core or excisional biopsy prior to the
start of treatment. Other Inclusion Criteria May Apply

Exclusion Criteria:

- Richter's transformation (DLBCL arising in the setting of prior chronic lymphocytic
leukemia) or Primary Mediastinal B cell Lymphoma (PMBCL)

- History or presence of clinically relevant Central Nervous System pathology such as
epilepsy, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's
disease, cerebellar disease, organic brain syndrome, or psychosis.

- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in
dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of protocol specified
therapy.

- Has undergone prior allogeneic HSCT:

- within the last 5 years OR

- greater than 5 years ago but has active graft versus host disease (GvHD)
requiring systemic treatment.

- Has received autologous HSCT within 6 weeks prior to start of treatment. Other
Exclusion Criteria May Apply.